WTAP and metabolic dysfunction-associated steatotic liver disease: However, the expression of WTAP, YTHDC1 and FASN was increased in NAFLD/NASH/HCC samples (Fig. 7A, B), indicating m6A-dependent downregulation of AP-2α during the inflammation-cancer progression.